Dr. Valentino’s COVID-19 Town Hall Webinar
COVID-19 / Coronavirus
On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community. You can watch the webinar in…
GLHF Letter to the Community on COVID-19
COVID-19 / Coronavirus, GLHF News
Dear GLHF Community Members, We are thinking of you every day. As we navigate this current health crisis together, our primary concern is,…
Health and Wellness Update from NHF’s Dr. Leonard Valentino
COVID-19 / Coronavirus
I know many of you are overwhelmed with often-conflicting information on the COVID-19 virus. As a doctor and researcher, the health of…
Coverage Concerns and Unanswered Questions: We Get It
COVID-19 / Coronavirus
As a community, we know how important it is for people with bleeding disorders to maintain comprehensive health insurance. Amid the uncertainty…
Three Concizumab Trials Halted by Novo Nordisk
Industry News & Research
Novo Nordisk recently announced that they have “paused” three clinical trials for their investigational subcutaneous therapy concizumab. The therapy is developed using…
Updates on Product Availability During COVID-19 Outbreak
COVID-19 / Coronavirus
NHF will be posting all communications from pharmaceutical companies regarding any potential affects that the COVID-19 pandemic could have on the manufacture…
Statement from Len Valentino on COVID-19
COVID-19 / Coronavirus
As we continue to monitor the COVID-19 outbreak in the US and around the world, we understand the uncertainty that it may…
Takeda Responds to HFA-NHF Letter on VONVENDI Recall
As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U….
NHF Letter to the Community on COVID-19
COVID-19 / Coronavirus
The greatest asset at NHF is the community we serve – our family of staff and volunteers. We are aware of the…
MASAC Letter to the Community Regarding the Coronavirus Disease 2019
COVID-19 / Coronavirus
The Centers for Disease Control and Prevention (CDC) is responding to the rapidly evolving situation of the outbreak of respiratory disease (COVID-19)…
Medexus Acquires XINITY® from Aptevo
Industry News & Research
Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S….
Partners in Bleeding Disorders Education Program Launches Revised Module
Industry News & Research
The Partners in Bleeding Disorders Education Program has announced the launch a new version of “Understanding Hemophilia,” a six-part online learning activity for clinicians…